Summary of Expertise, Experience, and Affiliations and Interests for the Scientific Advisory Panel on Diclectin (SAP-Diclectin)

June 2, 2016


The following table summarizes the information about expertise, experience, and affiliations and interests relevant to the Scientific Advisory Panel on Diclectin declared by panel members. Health Canada considered these declarations as part of the selection process. The Health Products and Food Branch has made this summary available as part of its commitment to be transparent about the membership of its advisory bodies.

Assessment of affiliations and interests prior to each meeting

Prior to each panel meeting, Health Canada assesses members' affiliations and interests, including direct financial interests, as they may apply to agenda items for discussion. Depending on the nature of the member's affiliations and interests, the Chair of the panel in consultation with other members of the panel may limit the participation of a member in the meeting or ask him/her to make a verbal statement of affiliations and interests at the beginning of the meeting. Members' affiliations and interests are reviewed and updated as required based on changes in the status of their affiliations and interests.

In accordance with the Health Products and Food Branch Review of Regulated Products: Policy on Public Input and Guidance on Advisory Bodies, a person with a direct financial interest in the outcome of a review of a regulated product may be a member of an advisory body whose broader mandate encompasses matters of policy, management, or program development. However, such a member would not be asked to participate in any discussion, formulation of advice, or recommendations to Health Canada relating to that review.

Indicated Perspective/Sector and Expertise/Experience


  • Health professional
  • Academia
  • Research


  • Biostatistics
  • Obstetrics and Gynecology
  • Family Medecine

I. Direct financial interests

  1. Current employment, investments in companies, partnerships, equity, royalties, joint ventures, trusts, real property, stocks, shares, or bonds with the regulated industry.

II. Indirect financial interests

  1. Within the past five years, payment from the regulated industry for work done or being done, including past employment, contracts, or consulting; or financial support including research support, personal education grants, contributions, fellowships, sponsorships, and honoraria.Footnote 1
  2. Within the past five years, materials, discounted products, gifts, or other benefits, or attendance at meetings where all or part of the travel and accommodation costs were provided by the regulated industry.Footnote 2
  3. Within the last three years, grants or other funding from the regulated industry to any of the organizations where you are currently employed or participate in internal decision making.Footnote 3

III. Intellectual interests

  1. Within the last five years, any formal advice or opinion to industry, a government organization, or a non-government organization.
  2. Within the last five years, any published or publicly stated point of view.
  3. Current professional or volunteer affiliations such as membership of professional societies, lobbying, public interest, or advocacy groups.

IV. Other affiliations and interests

  1. Any other affiliations and interests or potential circumstances that might give a well-informed member of the public reasonable grounds for concern regarding the integrity and objectivity of your participation.
Name and Indicated Sector and Expertise Summary of Responses
Dr. Mitchell A.H. Levine BSc, MSc, MD, FRCPC, FISPE, FACP Perspective/Sector
Academia, research

Pharmacology, Medicine, Clinical Epidemiology & Biostatistics
1) NO 2) YES 3) NO 4) NO 5) YES 6) NO 7) NO 8) NO

The Director of "PATH", a research unit at McMaster University and St. Joseph's Healthcare Hamilton.  Does not have any funds directly and personally procured from the pharmaceutical industry, but others from faculty have funds for research projects and student support.

In 2014-2015 funds had been received from ROCHE for a research project.

No grants related to product(s) relevant to this advisory body (some grants related to Oncology therapies and Cardiovascular therapies).
  • Vice-chair of Patented Medicine Prices Review Board.
  • Conducted projects for Canadian Agency For Drugs And Technologies In Health (CADTH).
  • Advisor/Consultant for Ontario Drug Benefit Program.
  • Expert testimony in class action lawsuit for ABBOTT (Re: clarithromycin).
Dr. Karen Fung Kee Fung MD, FRCSC, MHPE Perspective/Sector
Academia, research

Maternal-Fetal Medicine
1) NO 2) NO 3) NO 4) NO 5) NO 6) NO 7) NO 8) NO

Dr. Allan Donner, PhD, FRSC Perspective/Sector
Academia, research

Epidemiology and Biostatistics
1) NO 2) NO 3) NO 4) NO 5) NO 6) NO 7) NO 8) NO

George A. Wells, MSc, PhD Perspective/Sector
Academia, research

Epidemiology, Public Health, Biostatistics
1) NO 2) NO 3) NO 4) NO 5) NO 6) NO 7) NO 8) NO


Page details

Date modified: